Sight Diagnostics
Sight Diagnostics is an Israeli medical-device and diagnostics company, founded in 2011 and headquartered in Tel Aviv, that built Sight OLO — an FDA 510(k)-cleared, CE-marked point-of-care hematology analyzer producing a 19-parameter, five-part-differential Complete Blood Count from two drops of capillary or venous blood in about ten minutes. OLO replaces reagent-based flow cytometry with digital microscopy and machine vision: it images the sample across five illumination channels (405nm, 517nm and 633nm brightfield plus 365nm and 460nm fluorescence) and classifies cells with computer-vision models rather than impedance or optical scatter. The company raised roughly $124M across six rounds and has more recently repositioned around live immune-cell analysis and "immune signatures". Sight Diagnostics is an instrument and clinical-workflow business, not a software platform: it publishes no public API, no developer portal, no SDKs and no machine-readable contract. Device connectivity to LIS/EMR systems is delivered as a customer integration engagement rather than as a documented public interface, so there is no developer surface to profile.
Sight Diagnostics is profiled on the APIs.io network. Tagged areas include Company, Healthcare, Medical Devices, Diagnostics, and Hematology.
Kin Score
MCP Servers 1
Model Context Protocol servers that expose these APIs to AI agents.
Security Posture 1
Authentication, domain security, vulnerability disclosure, and trust-center signals.
Resources
Agent Surfaces 2
MCP servers, agent skills, and machine-readable catalogs
Build 1
SDKs, sample code, and the tooling you integrate with
Access & Security 1
Authentication, authorization, and security posture
Company 2
The organization behind the API
Source (apis.yml)
Work with this as data
Every provider here is available over the APIs.io API and to AI agents over MCP.